Phase II Study of Crenolanib (CP-868,596), for the Treatment of Patients With Advanced Gastrointestinal Stromal Tumors With the D842-related Mutations and Deletions in the PDGFRA Gene

This study has been completed.
Information provided by (Responsible Party):
Arog Pharmaceuticals, Inc. Identifier:
First received: November 17, 2010
Last updated: November 4, 2014
Last verified: November 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)